Pharmacogenetics in chronic heart failure: new developments and current challenges.
Pharmacogenetics in chronic heart failure: new developments and current challenges.
复制标题
DOI：
10.1007/s11897-011-0076-2
复制
发表时间：
2012-03
影响因子：
--
通讯作者：
Lanfear, David E
中科院分区：
文献类型：
--
作者：
Talameh, Jasmine A;Lanfear, David E
个体患者对慢性心力衰竭(HF)药物治疗的反应是高度不同的。这种变异性不能完全用临床特征来解释，遗传变异可能起到一定作用。因此，本综述的目的是1)总结主要的HF药物治疗类别(即β-受体阻滞剂、血管紧张素转换酶抑制剂、地高辛和环状利尿剂)的背景药物遗传学文献，2)根据先前的发现评价HF药物遗传学文献的最新进展，3)讨论HF药物遗传学数据及其临床应用的挑战和结论。
The individual patient responses to chronic heart failure (HF) pharmacotherapies are highly variable. This variability cannot be entirely explained by clinical characteristics, and genetic variation may play a role. Therefore the purpose of this review is to 1) summarize the background pharmacogenetic literature for major HF pharmacotherapy classes (i.e. beta-blockers, angiotensin converting enzyme inhibitors, digoxin, and loop diuretics), 2) evaluate recent advances in the HF pharmacogenetic literature in the context of previous findings, and 3) discuss the challenges and conclusions for HF pharmacogenetic data and its clinical application.